<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264107</url>
  </required_header>
  <id_info>
    <org_study_id>CLV-409</org_study_id>
    <nct_id>NCT01264107</nct_id>
  </id_info>
  <brief_title>An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine</brief_title>
  <official_title>An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With
      Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with sustained antiviral activity effect</measure>
    <time_frame>at week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of sAg</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of sAg loss</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HBV DNA form the baseline</measure>
    <time_frame>at week 48</time_frame>
    <description>(log copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ALT normalization</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HBeAg loss/seroconversion</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses
        With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients is currently clevudine treatment.

          2. Patients with HBV DNA ï¼œ 300 cpoies/mL and ALT normal Showing Muscle-related Symptom
             Who received Clevudine

          3. Patient who is able to give written informed consent prior to study start and to
             comply with the study requirements.

        Exclusion Criteria:

          1. Patient is currently receiving antiviral, immunomodulatory, cytotoxic or
             corticosteroid therapy.

          2. Patient is pregnant or breast-feeding.

          3. Patient has a significant gastrointestinal, renal, decompensated liver,
             bronchopulmonary, neurological, cardiac, oncologic(except HCC)or allergic disease.

          4. Patient, in the opinion of the investigator, unsuitable for the study.

          5. Showing Muscle-related Symptom who any other evidence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soon Koo Baik</name>
      <address>
        <city>Wonju, Kangwon-do 162 Ilsan-dong, Wonju, Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Hee Won Yoo</name_title>
    <organization>Bukwang Pharm. Co. Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

